Abstract:Objective: The traditional Chinese medicine Anluohuaxianwan (ALHXW) has been used to treat liver fibrosis induced by chronic hepatitis B virus (HBV) infection. However, the anti-fibrosis mechanisms of ALHXW remain to be investigated. This study used a rat model of carbon tetrachloride (CCl(4))-induced liver fibrosis to explore the potential antifibrogenic mechanisms of ALHXW. Methods: Twenty-seven male Wistar rats were randomly assigned to control group, model group, and treatment group (n = 9 per group). Rats in the model and treatment group were injected intraperitoneally with 40% CCl(4)(2 ml/kg), and rats in the control group were administered saline twice a week for 6 weeks. Starting at week 4 following model construction, rats in the treatment group received daily gavages with ALHXW solution (concentration 0.15 g/ml) daily, while rats in the control and model groups were given saline for a total of 6 weeks. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured from blood samples collected at the end of weeks 3, 6 and 9. Histopathological examination of liver tissue was performed to evaluate liver fibrosis at week 9. At the same time, the mRNA expression of TGF-β1 and Smads in liver tissues was quantified by real-time reverse transcription polymerase chain reaction (RT-PCR), and TGF-β1 protein level in the liver was measured by Western blot. Inter-group comparison was performed using analysis of variance (ANOVA) when the continuous data were normally distributed and satisfied the homogeneity of variance; otherwise, nonparametric tests were used. Categorical data were compared between groups using nonparametric tests. Results: ALHXW markedly alleviated liver injury in the treatment group after 3 weeks of therapy as indicated by a significantly reduced level of ALT compared with the model group [(162.98 ± 73.14)U/L vs (322.52 ± 131.76)U/L, P = 0.047], and a 39.8% reduction in AST level compared with the model group[ (537.56 ± 306.06)U/L vs (892.98 ± 358.19)U/L, P = 0.053]. Moreover, at the end of the 6-week therapy, histopathological diagnosis showed that liver fibrosis was significantly reduced in the ALHXW-treated group compared with that in the model group (P = 0.002). The relative expression of TGF-β1 mRNA and protein in the liver were significantly lower in ALHXW-treated rats than that in model rats (1.34 ± 0.31 vs 1.78 ± 0.45, P = 0.025; 0.39 ± 0.02 vs 0.57 ± 0.04, P = 0.003). Conclusion: ALHXW treatment can reverse CCl(4)-induced liver fibrosis in rats. Its mechanisms of anti-fibrosis may occur through the inhibition of TGF-β1 synthesis and TGF-β1/Smads signaling pathway, which in turn suppress the activation of hepatic stellate cells and thereby reverses fibrosis.

BML-11, A Lipoxin Receptor Agonist, Protected Carbon Tetrachloride-Induced Hepatic Fibrosis in Rats

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

Protective Effects of Bml-111, A Lipoxin A(4) Receptor Agonist, on Carbon Tetrachloride-Induced Liver Injury in Mice

BML-111 Equilibrated ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas Axis to Protect Hepatic Fibrosis in Rats.

BML-111 Protected LPS/D-GalN-Induced Acute Liver Injury in Rats.

BML-111 Suppresses TGF-β1-induced Lung FIbroblast Activation Invitro and Decreases Experimental Pulmonary Fibrosis Invivo

BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system.

BML-111 ameliorates endotoxin-induced liver injury through increasing prostaglandin J 2 production via ERK / COX 2 pathway

BML-111, a Lipoxin Receptor Agonist, Modulates the Immune Response and Reduces the Severity of Collagen-Induced Arthritis.

Lycium Barbarum Polysaccharides Improve CCl4-induced Liver Fibrosis, Inflammatory Response and TLRs/NF-kB Signaling Pathway Expression in Wistar Rats

Inhibition of the Translocation and Extracellular Release of High-Mobility Group Box 1 Alleviates Liver Damage in Fibrotic Mice in Response to D-galactosamine/lipopolysaccharide Challenge

Dual TBK1/IKKɛ inhibitor amlexanox attenuates the severity of hepatotoxin‐induced liver fibrosis and biliary fibrosis in mice

Ligustroflavone Ameliorates CCl4-induced Liver Fibrosis Through Down-Regulating the TGF-β/Smad Signaling Pathway.

Effects Of 18 Alpha-Glycyrrhizin On Tgf-Beta 1/Smad Signaling Pathway In Rats With Carbon Tetrachloride-Induced Liver Fibrosis

Β-Catenin/tcf4 Inhibitors ICG-001 and LF3 Alleviate BDL-induced Liver Fibrosis by Suppressing LECT2 Signaling

BML-111, a Lipoxin Receptor Agonist, Ameliorates ‘Two-Hit’-induced Acute Pancreatitis-Associated Lung Injury in Mice by the Upregulation of Heme Oxygenase-1

Lipoxin A4 Inhibited the Activation of Hepatic Stellate Cells -T6 Cells by Modulating Profibrotic Cytokines and NF-κB Signaling Pathway.

Effects of 18Α-Glycyrrhizin on TGF-β1/Smad Signaling Pathway in Rats with Carbon Tetrachloride-Induced Liver Fibrosis.

[Effects of Anluohuaxianwan on Transforming Growth Factor-Β1 and Related Signaling Pathways in Rats with Carbon Tetrachloride-Induced Liver Fibrosis].

BML-111 Attenuates Hemorrhagic Shock-Induced Acute Lung Injury Through Inhibiting Activation of Mitogen-Activated Protein Kinase Pathway in Rats.

BML-111 Attenuates Acute Lung Injury in Endotoxemic Mice.